Literature DB >> 8529093

Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.

J Chen1, J Lin, A J Levine.   

Abstract

BACKGROUND: Mdm-2, a zinc finger protein, negatively regulates the p53 tumor suppressor gene product by binding to it and preventing transcriptional activation (16).
MATERIALS AND METHODS: Assays for p53 mediated transcription, repression and activation by mutant and wild-type p53 proteins were used to measure the ability of mdm-2 to block each activity.
RESULTS: Mdm-2 was able to inhibit all three functions of the wild-type and mutant p53 activities; transcriptional activation by the wild-type protein, transcriptional activation by the mutant p53 protein, and repression by the wild-type protein.
CONCLUSIONS: The mdm protein binds to the amino terminal portion of the p53 protein and, in so doing, blocks the ability of p53 to interact with the transcriptional machinery of the cell (23). The mdm-2 protein binds to both leucine-tryptophan residues at amino acids 22 and 23, from the amino terminal end of the protein, and in so doing, prevents all p53 functions. The ability of a mutant p53 protein to transactivate a multidrug resistance-1 gene promoter is blocked by mdm-2 and the ability of the wild-type p53 protein to repress transcription of some genes is also blocked by the mdm-2 protein. Thus, all three functions of the p53 protein-transcriptional activation, repression and mutant protein activation-require the p53 amino terminal domain functions and are regulated by the mdm-2 protein in a cell. When mdm-2 is overproduced, resulting in a tumor or transformation of a cell, all of the p53 activities are inactivated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529093      PMCID: PMC2229942     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  42 in total

1.  Rearrangement of the p53 gene in human osteogenic sarcomas.

Authors:  H Masuda; C Miller; H P Koeffler; H Battifora; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.

Authors:  C M Gorman; G T Merlino; M C Willingham; I Pastan; B H Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

3.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

Authors:  D Wolf; N Harris; V Rotter
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

4.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

6.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

Authors:  J Lin; J Chen; B Elenbaas; A J Levine
Journal:  Genes Dev       Date:  1994-05-15       Impact factor: 11.361

7.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.

Authors:  D H Mack; J Vartikar; J M Pipas; L A Laimins
Journal:  Nature       Date:  1993-05-20       Impact factor: 49.962

8.  Wild-type p53 binds to the TATA-binding protein and represses transcription.

Authors:  E Seto; A Usheva; G P Zambetti; J Momand; N Horikoshi; R Weinmann; A J Levine; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Authors:  C A Finlay
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

10.  The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.

Authors:  R L Zastawny; R Salvino; J Chen; S Benchimol; V Ling
Journal:  Oncogene       Date:  1993-06       Impact factor: 9.867

View more
  71 in total

1.  Identification of a sequence element from p53 that signals for Mdm2-targeted degradation.

Authors:  J Gu; D Chen; J Rosenblum; R M Rubin; Z M Yuan
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.

Authors:  L McKendrick; D Milne; D Meek
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

Review 3.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

4.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 6.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

7.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

8.  Critical role for a central part of Mdm2 in the ubiquitylation of p53.

Authors:  Erik Meulmeester; Ruth Frenk; Robert Stad; Petra de Graaf; Jean-Christophe Marine; Karen H Vousden; Aart G Jochemsen
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Regulation of p53 stability and function by the deubiquitinating enzyme USP42.

Authors:  Andreas K Hock; Arnaud M Vigneron; Stephanie Carter; Robert L Ludwig; Karen H Vousden
Journal:  EMBO J       Date:  2011-11-15       Impact factor: 11.598

10.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.

Authors:  Michael Overholtzer; Pulivarthi H Rao; Reyna Favis; Xin-Yan Lu; Michael B Elowitz; Francis Barany; Marc Ladanyi; Richard Gorlick; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.